Michael Gallo

US Patent:

6395515, May 28, 2002

Filed:

Aug 6, 1999

Appl. No.:

09/369635

Inventors:

Aya Jakobovits - Menlo Park CA
Michael Lajos Gallo - San Jose CA
Xiao-Ping Yang - Foster City CA

Assignee:

Abgenix, Inc. - Fremont CA
Japan Tobacco, Inc. - Tokyo

International Classification:

C12P 2104

US Classification:

435 696, 4353201, 435325, 435455, 536 231, 800 4, 800 14, 800 25

Abstract:

Switch regions derived from an immunoglobulin (Ig) gene are used to direct recombination between a targeting construct containing a promoter, a switch region (S ), and 2) a target locus minimally containing a promoter, a switch region (S ), and a target sequence.

US Patent:

7807798, Oct 5, 2010

Filed:

Nov 4, 2005

Appl. No.:

11/267860

Inventors:

Aya Jakobovits - Menlo park CA, US
Xiao-Dong Yang - Palo Alto CA, US
Michael Gallo - San Jose CA, US
Xiao-Chi Jia - San Mateo CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA

International Classification:

C12P 21/08

US Classification:

53038815, 53038822

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.

US Patent:

8227580, Jul 24, 2012

Filed:

Apr 26, 2010

Appl. No.:

12/767086

Inventors:

Aya Jakobovits - Menlo Park CA, US
Xiao-Dong Yang - Palo Alto CA, US
Michael Gallo - San Jose CA, US
Xiao-Chi Jia - San Mateo CA, US

Assignee:

Amgen Inc - Thousand Oaks CA

International Classification:

C07K 16/28
C07K 16/00

US Classification:

53038822, 5303871

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.

US Patent:

20020173629, Nov 21, 2002

Filed:

Nov 5, 1998

Appl. No.:

09/187693

Inventors:

AYA JAKOBOVITS - MENLO PARK CA, US
XIAO-DONG YANG - PALO ALTO CA, US
MICHAEL GALLO - SAN JOSE CA, US
XIAO-CHI JIA - SAN MATEO CA, US

International Classification:

C07K016/00
C12P021/08

US Classification:

530/388220, 530/387100

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.

US Patent:

20030190751, Oct 9, 2003

Filed:

Apr 3, 2002

Appl. No.:

10/115668

Inventors:

Aya Jakobovits - Menlo Park CA, US
Michael Gallo - San Jose CA, US
Xiao-Ping Yang - Foster City CA, US

International Classification:

C12P021/02
C12N005/06
C12N015/85

US Classification:

435/455000, 435/069100, 435/320100, 435/326000

Abstract:

Switch regions derived from an immunoglobulin (Ig) gene are used to direct recombination between a targeting construct containing a promoter, a switch region (S), and 2) a target locus minimally containing a promoter, a switch region (S), and a target sequence.

US Patent:

20050100546, May 12, 2005

Filed:

Dec 22, 2004

Appl. No.:

11/021795

Inventors:

Aya Jakobovits - Menlo Park CA, US
Xiao-Dong Yang - Palo Alto CA, US
Michael Gallo - San Jose CA, US
Xiao-Chi Jia - San Mateo CA, US

International Classification:

A61K039/395
C07K016/28

US Classification:

424143100, 530388220

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.

US Patent:

52878643, Feb 22, 1994

Filed:

Oct 5, 1992

Appl. No.:

7/956119

Inventors:

Michael Gallo - Union NJ

International Classification:

A61K 713

US Classification:

132208

Abstract:

The present invention provides a frosting foil for use in connection with frosting and/or coloring a subject's hair. The frosting foil includes a sleeve, an adhesive surface, and a backing material. The sleeve is sized to receive the tail of a tail comb so that a stylist may pick up and properly place the foil at a strand of hair desired to be treated. The adhesive attaches the foil to the strand of hair to prevent movement of the foil. Further, the adhesive permits the foil to be folded into place so that all of the foils may be placed prior to the addition of any coloring agent. After placement of the foils, each foil may be sequentially opened and a coloring agent placed on the strand of the hair contained in the foil.

US Patent:

62358839, May 22, 2001

Filed:

May 5, 1997

Appl. No.:

8/851362

Inventors:

Aya Jakobovits - Menlo Park CA
Xiao-Dong Yang - Palo Alto CA
Michael Gallo - San Jose CA
Xiao-Chi Jia - San Mateo CA

Assignee:

Abgenix, Inc. - Fremont CA

International Classification:

C07K 1628

US Classification:

53038822

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided.